Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768057 | 0.90 | TRPV4 (0.37) | HTR4ADRB2CHRM3SLC2A1TRPV4 | |
| SCHEMBL381439 | 0.86 | SLC2A1 (0.48) | ADRB2CHRM3SLC2A1 | |
| SCHEMBL768530 | 0.86 | ADRB2 (0.36) | HTR4ADRB2CHRM3SLC2A1DRD4 | |
| SCHEMBL768563 | 0.85 | CHRM2 (0.38) | ADRB2CHRM3SLC2A1TRPV4DRD2 | |
| SCHEMBL768450 | 0.81 | SLC2A1 (0.36) | ADRB2CHRM3SLC2A1TRPV4DRD4 | |
| SCHEMBL768337 | 0.79 | CHRM3 (0.42) | CHRM3SLC2A1DRD2 | |
| SCHEMBL768998 | 0.79 | HTR2A (0.35) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL768154 | 0.79 | TRPV4 (0.33) | SLC2A1TRPV4 | |
| SCHEMBL769390 | 0.78 | TRPV4 (0.36) | ADRB2CHRM3TRPV4DRD4DRD2 | |
| SCHEMBL783895 | 0.78 | SLC2A1 (0.52) | ADRB2CHRM3SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | HTR4 571/4885ADRB2 47/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.